147 related articles for article (PubMed ID: 38241595)
21. [The Expression of RTN1 in Lung Adenocarcinoma and
Its Effect on Immune Microenvironment].
Zhu S; Zu L; Xu S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
[TBL] [Abstract][Full Text] [Related]
22. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
[TBL] [Abstract][Full Text] [Related]
23. A novel immune-related prognostic signature in epithelial ovarian carcinoma.
Su T; Zhang P; Zhao F; Zhang S
Aging (Albany NY); 2021 Apr; 13(7):10289-10311. PubMed ID: 33819196
[TBL] [Abstract][Full Text] [Related]
24. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
25. Mitochondrial AAA protease gene associated with immune infiltration is a prognostic biomarker in human ovarian cancer.
Liao WT; Chu PY; Su CC; Wu CC; Li CJ
Pathol Res Pract; 2022 Dec; 240():154215. PubMed ID: 36423401
[TBL] [Abstract][Full Text] [Related]
26. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
[TBL] [Abstract][Full Text] [Related]
27. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
28. ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC.
Yang Z; Tian H; Bie F; Xu J; Zhou Z; Yang J; Li R; Peng Y; Bai G; Tian Y; Chen Y; Liu L; Fan T; Xiao C; Zheng Y; Zheng B; Wang J; Li C; Gao S; He J
Front Immunol; 2021; 12():788985. PubMed ID: 34992605
[TBL] [Abstract][Full Text] [Related]
29. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of
Jiang S; Yang Y; Zhang Y; Ye Q; Song J; Zheng M; Li X
Dis Markers; 2022; 2022():9719671. PubMed ID: 35186171
[TBL] [Abstract][Full Text] [Related]
31. Exploring the role of miR-200 family in regulating CX3CR1 and CXCR1 in lung adenocarcinoma tumor microenvironment: implications for therapeutic intervention.
Sharma A; Singh P; Jha R; Almatroodi SA; Alrumaihi F; Rahmani AH; Alharbi HO; Dohare R; Syed MA
Sci Rep; 2023 Sep; 13(1):16333. PubMed ID: 37770496
[TBL] [Abstract][Full Text] [Related]
32. Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer.
Xu Y; Chen L; Xu B; Xiong Y; Yang M; Rui X; Shi L; Wu C; Jiang J; Lu B
Cell Physiol Biochem; 2017; 41(2):475-483. PubMed ID: 28214872
[TBL] [Abstract][Full Text] [Related]
33. Wiskott-Aldrich syndrome gene as a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.
Ding G; Wang T; Liu S; Zhou Z; Ma J; Wu J
Front Immunol; 2023; 14():1102824. PubMed ID: 37122750
[TBL] [Abstract][Full Text] [Related]
34. Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
Zhang J; Yu S; Li Q; Wang Q; Zhang J
Gynecol Oncol; 2022 Mar; 164(3):566-576. PubMed ID: 35042621
[TBL] [Abstract][Full Text] [Related]
35. Identification of key molecular markers in epithelial ovarian cancer by integrated bioinformatics analysis.
Qin W; Yuan Q; Liu Y; Zeng Y; Ke D; Dai X; Shuai Y; Hu J; Shi H
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):983-994. PubMed ID: 34794761
[TBL] [Abstract][Full Text] [Related]
36. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.
Jiang Y; Chen S; Li Q; Liang J; Lin W; Li J; Liu Z; Wen M; Cao M; Hong J
Front Immunol; 2021; 12():612139. PubMed ID: 33679751
[TBL] [Abstract][Full Text] [Related]
37. Role of the KRT7 Biomarker in Immune Infiltration and Paclitaxel Resistance in Ovarian.
Wang S; Li H; Li M; Liu X; Yu S; Huang H; Wang X
Altern Ther Health Med; 2023 Jul; 29(5):132-140. PubMed ID: 37023314
[TBL] [Abstract][Full Text] [Related]
38. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
39. CX3CR1 delineates temporally and functionally distinct subsets of myeloid-derived suppressor cells in a mouse model of ovarian cancer.
Hart KM; Usherwood EJ; Berwin BL
Immunol Cell Biol; 2014 Jul; 92(6):499-508. PubMed ID: 24613975
[TBL] [Abstract][Full Text] [Related]
40. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
